Inactive Instrument

Other languages TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.	01/23/01
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
Sector Update: Health Care Stocks Hit by Late Selling	07/23/07
Top Midday Decliners	07/23/07
Top Midday Gainers	07/23/07
Sector Update: Health Care Stocks Back on Positive Ground	07/23/07
Sector Update: Health Care Stocks Edge Higher Premarket Monday	06/23/06
Upcoming Powell Testimony to Congress Underpins US Equity Futures	06/23/06
Top Premarket Decliners	06/23/06
Adaptimmune Therapeutics, TCR2 Therapeutics to Merge in All-Stock Transaction	06/23/06
Adaptimmune and TCR2 Therapeutics Inc. Announce Strategic Combination to Create Preeminent Cell Therapy Company for Solid Tumors	06/23/06
TCR2 Therapeutics Inc. Appoints Peter Olagunju as Chief Operating Officer	04/23/04
TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	08/22/08
Tcr2 Therapeutics Inc. Announces Positive Topline Results from the Phase 1 Portion of the Gavo-Cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors	28/22/28
TCR2 Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	08/22/08
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12
TCR2 Appoints Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer	22/22/22
TCR2 Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22/22/22
TCR2 Therapeutics Inc. Announces Appointment of Rosemary Harrison as Chief Business and Strategy Officer	13/22/13
TCR2 Therapeutics Appoints Chief Business and Strategy Officer	12/22/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages TCR2 Therapeutics Inc.

Equities

TCRR

US87808K1060

Other languages

Filters